RE: New Contract Award Notice: Yourgene DPYD and CFEU kits20 Jun 2026 13:15
The Contract Award Details
Awarding Body: Cambridge University Hospitals NHS Foundation Trust
Recipient: Yourgene Health (Novacyt's genomic medicine subsidiary)
The Products: Yourgene DPYD and CFEU kits
Why This Specific Win Is Highly Strategic: The nature of this award is an absolute proof-of-concept for Novacyt’s long term strategy
- Validation of the DPYD Rollout: Novacyt only just commercially launched the upgraded Yourgene Insight DPYD assay last month (May 19, 2026). Winning a contract with a massive, prestigious tier-1 trust like Cambridge University Hospitals right out of the gate is a massive clinical validation.
- The "Precision Medicine" Pivot is Working: The DPYD assay tests cancer patients before chemotherapy to ensure they don't have a specific genetic mutation that makes the treatment toxic or fatal. This contract proves that Novacyt is successfully replacing dead pandemic revenue with high-margin, repeatable clinical oncology revenue.
- CFEU Inclusion: Incorporating Cystic Fibrosis Europe (CFEU) screening kits alongside DPYD demonstrates that Cambridge is buying deeper into Yourgene's wider reproductive and genomic health portfolio.